BIOMAT Database Logo BIOMAT Database Logo

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation. 2009

Koichi Azuma, and Tetsuro Sasada, and Akihiko Kawahara, and Satoshi Hattori, and Takashi Kinoshita, and Sinzo Takamori, and Masao Ichiki, and Youhei Imamura, and Jiro Ikeda, and Masayoshi Kage, and Michihiko Kuwano, and Hisamichi Aizawa
Department of Internal Medicine, Division of Respirology, Neurology, and Rheumatology, Kurume University School of Medicine, Kurume, Fukuoka, Japan. azuma@med.kurume-u.ac.jp

BACKGROUND The expression of excision repair cross-complementation group 1 (ERCC1) is reported to be correlated with resistance to platinum-based drugs. Class III beta-tubulin is reported to be correlated with resistance to taxanes. METHODS In the present study, we evaluated whether ERCC1 and class III beta-tubulin expression could be used to predict progression-free and/or overall survival in 34 patients with locally advanced non-small cell lung cancer (NSCLC) receiving concurrent chemoradiation therapy with cisplatin and docetaxel, and immunohistochemistry was used to examine the expression of these two proteins in tumor samples obtained from the patients. RESULTS Immunostaining for ERCC1 and class III beta-tubulin was positive in 16 and 12 patients, respectively. A significant correlation was observed between ERCC1 expression and response to chemotherapy (P = 0.012), and between class III beta-tubulin expression and histology (P = 0.029). Patients negative for ERCC1 had a significantly longer median progression-free (62.5 vs. 36 weeks, P = 0.009), but not overall (171 vs. 50.5 weeks, P = 0.208), survival than those positive for ERCC1. Expression of class III beta-tubulin was not correlated with progression-free or overall survival (P = 0.563 and P = 0.265, respectively). Multivariate analysis adjusting for possible confounding factors showed that negative ERCC1 expression (hazard ratio = 3.972, P = 0.009) was a significantly favorable factor for progression-free survival. CONCLUSIONS This retrospective study indicates that immunostaining for ERCC1 may be useful for predicting survival in NSCLC patients receiving concurrent chemoradiotherapy with cisplatin and docetaxel, and can provide information critical for planning personalized chemotherapy.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004268 DNA-Binding Proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. DNA Helix Destabilizing Proteins,DNA-Binding Protein,Single-Stranded DNA Binding Proteins,DNA Binding Protein,DNA Single-Stranded Binding Protein,SS DNA BP,Single-Stranded DNA-Binding Protein,Binding Protein, DNA,DNA Binding Proteins,DNA Single Stranded Binding Protein,DNA-Binding Protein, Single-Stranded,Protein, DNA-Binding,Single Stranded DNA Binding Protein,Single Stranded DNA Binding Proteins
D004720 Endonucleases Enzymes that catalyze the hydrolysis of the internal bonds and thereby the formation of polynucleotides or oligonucleotides from ribo- or deoxyribonucleotide chains. EC 3.1.-. Endonuclease
D005260 Female Females

Related Publications

Koichi Azuma, and Tetsuro Sasada, and Akihiko Kawahara, and Satoshi Hattori, and Takashi Kinoshita, and Sinzo Takamori, and Masao Ichiki, and Youhei Imamura, and Jiro Ikeda, and Masayoshi Kage, and Michihiko Kuwano, and Hisamichi Aizawa
beta-Tubulin III mRNA expression and docetaxel sensitivity in non-small cell lung cancer.
December 2009, Clinical and investigative medicine. Medecine clinique et experimentale,
Koichi Azuma, and Tetsuro Sasada, and Akihiko Kawahara, and Satoshi Hattori, and Takashi Kinoshita, and Sinzo Takamori, and Masao Ichiki, and Youhei Imamura, and Jiro Ikeda, and Masayoshi Kage, and Michihiko Kuwano, and Hisamichi Aizawa
Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer.
May 2009, Cancer chemotherapy and pharmacology,
Koichi Azuma, and Tetsuro Sasada, and Akihiko Kawahara, and Satoshi Hattori, and Takashi Kinoshita, and Sinzo Takamori, and Masao Ichiki, and Youhei Imamura, and Jiro Ikeda, and Masayoshi Kage, and Michihiko Kuwano, and Hisamichi Aizawa
Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer.
October 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Koichi Azuma, and Tetsuro Sasada, and Akihiko Kawahara, and Satoshi Hattori, and Takashi Kinoshita, and Sinzo Takamori, and Masao Ichiki, and Youhei Imamura, and Jiro Ikeda, and Masayoshi Kage, and Michihiko Kuwano, and Hisamichi Aizawa
Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in Stage III non-small-cell lung cancer.
January 2002, International journal of radiation oncology, biology, physics,
Koichi Azuma, and Tetsuro Sasada, and Akihiko Kawahara, and Satoshi Hattori, and Takashi Kinoshita, and Sinzo Takamori, and Masao Ichiki, and Youhei Imamura, and Jiro Ikeda, and Masayoshi Kage, and Michihiko Kuwano, and Hisamichi Aizawa
Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer.
January 2009, Internal medicine (Tokyo, Japan),
Koichi Azuma, and Tetsuro Sasada, and Akihiko Kawahara, and Satoshi Hattori, and Takashi Kinoshita, and Sinzo Takamori, and Masao Ichiki, and Youhei Imamura, and Jiro Ikeda, and Masayoshi Kage, and Michihiko Kuwano, and Hisamichi Aizawa
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
July 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Koichi Azuma, and Tetsuro Sasada, and Akihiko Kawahara, and Satoshi Hattori, and Takashi Kinoshita, and Sinzo Takamori, and Masao Ichiki, and Youhei Imamura, and Jiro Ikeda, and Masayoshi Kage, and Michihiko Kuwano, and Hisamichi Aizawa
Concurrent docetaxel and thoracic radiation in non-small-cell lung cancer.
May 2002, Clinical lung cancer,
Koichi Azuma, and Tetsuro Sasada, and Akihiko Kawahara, and Satoshi Hattori, and Takashi Kinoshita, and Sinzo Takamori, and Masao Ichiki, and Youhei Imamura, and Jiro Ikeda, and Masayoshi Kage, and Michihiko Kuwano, and Hisamichi Aizawa
Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer.
December 2006, Cancer chemotherapy and pharmacology,
Koichi Azuma, and Tetsuro Sasada, and Akihiko Kawahara, and Satoshi Hattori, and Takashi Kinoshita, and Sinzo Takamori, and Masao Ichiki, and Youhei Imamura, and Jiro Ikeda, and Masayoshi Kage, and Michihiko Kuwano, and Hisamichi Aizawa
Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer.
March 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Koichi Azuma, and Tetsuro Sasada, and Akihiko Kawahara, and Satoshi Hattori, and Takashi Kinoshita, and Sinzo Takamori, and Masao Ichiki, and Youhei Imamura, and Jiro Ikeda, and Masayoshi Kage, and Michihiko Kuwano, and Hisamichi Aizawa
Class III Beta-tubulin Expression in Non-small Cell Lung Cancer: A Predictive Factor for Paclitaxel Response.
May 2015, Anticancer research,
Copied contents to your clipboard!